Which statement best describes NPH insulin?

NPH insulin is classified as an intermediate-acting insulin. This means that it has a longer duration of action compared to short-acting insulins and begins to work later than rapid-acting insulins. Typically, NPH insulin is administered subcutaneously, and it is not suitable for intravenous (IV) use due to its formulation and absorption characteristics. This insulin is commonly used to provide basal glycemic control, usually taken once or twice daily.

The characteristic duration and action profile of NPH insulin make it inappropriate for IV administration, which is reserved for rapid-acting insulins like regular insulin when immediate control is necessary. This distinction is vital for proper insulin management in diabetic patients, ensuring they receive the appropriate type of insulin based on their treatment needs.